I'm LongbridgeAI, I can summarize articles.MarketBeat's stock screener identifies seven medical stocks to watch on September 16th: Stryker, McKesson, Danaher, Gilead Sciences, Boston Scientific, Medtronic, and HCA Healthcare. These companies were selected based on having the highest dollar trading volume among medical sector stocks in recent days. The list includes major players in medical technology, pharmaceuticals, biotechnology, and hospital services.
- 3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most
Stryker, McKesson, Danaher, Gilead Sciences, Boston Scientific, Medtronic, and HCA Healthcare are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical manufacturers, biotechnology firms, medical-device makers, hospitals, and health insurers. Investors buy these stocks to gain exposure to the healthcare industry, though their performance can be affected by factors such as regulatory approvals, clinical-trial results, insurance policies, and healthcare demand. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Stryker (SYK)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
- Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?
Read Our Latest Research Report on SYK
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
- Beware the Death Cross: 3 Stocks Triggering This Spooky Signal
Read Our Latest Research Report on MCK
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read Our Latest Research Report on DHR
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read Our Latest Research Report on GILD
Boston Scientific (BSX)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Read Our Latest Research Report on BSX
Medtronic (MDT)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Read Our Latest Research Report on MDT
HCA Healthcare (HCA)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Read Our Latest Research Report on HCA
Further Reading
- MarketBeat's Top Five Stocks to Own in September 2026
- 5 Buy-and-Hold Stocks Built to Weather a Volatile Market
- Movado’s Turnaround Gains Momentum
- Qualcomm’s Discount Could Vanish If Its AI Bet Pays Off
- Micron’s AI Memory Boom Could Send Shares 100% Higher
- Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Stryker Right Now?
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
![]()
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Add As Preferred Source![]()
